BGM

Company Overview — What Does BGM Group Ltd. Do?

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China. BGM Group Ltd. (BGM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chen Xin and employs approximately 298 people. With a market capitalization of $94M, BGM is one of the notable companies in the Healthcare sector.

BGM Group Ltd. (BGM) Stock Rating — Reduce (April 2026)

As of April 2026, BGM Group Ltd. receives a Reduce rating with a composite score of 30.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BGM ranks #3,936 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BGM Group Ltd. ranks #659 of 839 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BGM Stock Price and 52-Week Range

BGM Group Ltd. (BGM) currently trades at $0.34. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is BGM Overvalued or Undervalued? — Valuation Analysis

BGM Group Ltd. (BGM) carries a value factor score of 42/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 1.43x, versus the sector average of 2.69x. The price-to-sales ratio is 0.61x, compared to 1.64x for the average Healthcare stock.

Overall, BGM's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

BGM Group Ltd. Profitability — ROE, Margins, and Quality Score

BGM Group Ltd. (BGM) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -14.2%, compared to the Healthcare sector average of -42.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -11.5% versus the sector average of -33.1%.

On a margin basis, BGM Group Ltd. reports gross margins of 16.4%, compared to 71.3% for the sector. The operating margin is -2.3% (sector: -65.2%). Net profit margin stands at -6.0%, versus -54.1% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BGM Debt, Balance Sheet, and Financial Health

BGM Group Ltd. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $10M.

BGM has a beta of 1.00, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for BGM Group Ltd. is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

BGM Group Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BGM Group Ltd. reported revenue of $25M and earnings per share (EPS) of $-0.20. Net income for the quarter was $-2M. Gross margin was 16.4%. Operating income came in at $-563,771.

In FY 2024, BGM Group Ltd. reported revenue of $25M and earnings per share (EPS) of $-0.20. Net income for the quarter was $-2M. Gross margin was 16.4%. Revenue grew -46.0% year-over-year compared to FY 2023. Operating income came in at $-563,771.

In FY 2023, BGM Group Ltd. reported revenue of $46M and earnings per share (EPS) of $-1.08. Net income for the quarter was $-8M. Gross margin was 3.8%. Revenue grew -28.3% year-over-year compared to FY 2022. Operating income came in at $-3M.

In FY 2022, BGM Group Ltd. reported revenue of $65M and earnings per share (EPS) of $0.03. Net income for the quarter was $1M. Gross margin was 9.6%. Revenue grew 13.6% year-over-year compared to FY 2021. Operating income came in at $2M.

Over the past 7 quarters, BGM Group Ltd. has experienced revenue contraction from $46M to $25M. Investors analyzing BGM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BGM Dividend Yield and Income Analysis

BGM Group Ltd. (BGM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BGM Momentum and Technical Analysis Profile

BGM Group Ltd. (BGM) has a momentum factor score of 3/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 56/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

BGM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BGM Group Ltd. (BGM) ranks #659 out of 839 stocks based on the Blank Capital composite score. This places BGM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.

Comparing BGM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BGM vs S&P 500 (SPY) comparison to assess how BGM Group Ltd. stacks up against the broader market across all factor dimensions.

BGM Next Earnings Date

No upcoming earnings date has been announced for BGM Group Ltd. (BGM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BGM? — Investment Thesis Summary

The quantitative profile for BGM Group Ltd. suggests caution. The quality score of 33/100 flags below-average profitability. Momentum is weak at 3/100, a headwind for near-term performance. High volatility (stability score 20/100) increases portfolio risk.

In summary, BGM Group Ltd. (BGM) earns a Reduce rating with a composite score of 30.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BGM stock.

Related Resources for BGM Investors

Explore more research and tools: BGM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BGM head-to-head with peers: BGM vs AZN, BGM vs SLGL, BGM vs HOLX.